Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

ATHE
Alterity Therapeutics Limited
stock NASDAQ ADR

At Close
May 15, 2026 3:59:56 PM EDT
4.03USD-13.704%(-0.64)76,879
3.41Bid   4.79Ask   1.38Spread
Pre-market
May 15, 2026 9:16:30 AM EDT
4.45USD-4.719%(-0.22)6,322
After-hours
May 15, 2026 4:44:30 PM EDT
4.01USD-0.496%(-0.02)134
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 28, 2022
07:13AM EST  Alterity : ATH434 Promising Small Molecule Drug Candidate Has Potential For Treating Multiple System Atrophy   RTTNews
07:08AM EST  Neuroprotective in Animal Model of Parkinsonian Disorder in the Journal of Parkinson's Disease   PR Newswire
05:44AM EST  Alterity Therapeutics Announces Publication Demonstrating that ATH434 is Neuroprotective in Animal Model of Parkinsonian Disorder in the Journal of Parkinson's Disease   Benzinga
Jan 27, 2022
07:45AM EST  Appendix 4C - Q2 FY22 Quarterly Cash Flow Report   PR Newswire
Jan 6, 2022
02:33PM EST  Mid-Afternoon Market Update: Gold Drops 2%; Berkeley Lights Shares Plummet   Benzinga
12:11PM EST  Mid-Day Market Update: Nasdaq Turns Higher; Vocera Communications Shares Surge   Benzinga
07:48AM EST  Alterity Therapeutics Granted New US Patent For Compounds For Neurodegenerative Diseases   RTTNews
07:30AM EST  Alterity Therapeutics Granted New US Patent for Compounds for Neurodegenerative   PR Newswire
05:06AM EST  Alterity Therapeutics Shares RIse 32% After Company Announced it Was Granted New US Patent for Compounds for Neurodegenerative Diseases Including Parkinson's and Alzheimer's   Benzinga
Jan 5, 2022
07:45AM EST  Alterity Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual   PR Newswire
Dec 14, 2021
07:27AM EST  Alterity Therapeutics New Zealand Medicines And Medical Devices Safety Authority Has Authorized Co.'s ATH434 Phase 2 Clinical Trial   Benzinga
07:27AM EST  Alterity Therapeutics Announces First Regulatory Authorization To Proceed With ATH434 Phase 2 Clinical Trial   RTTNews
07:25AM EST  Alterity Therapeutics Announces First Regulatory Authorization to Proceed with   PR Newswire
Nov 22, 2021
07:51AM EST  Alterity Therapeutics to Participate in Two Upcoming Investor Conferences   PR Newswire
Nov 9, 2021
11:35AM EST  Alterity Therapeutics Announces Presentation Of ATH434 At American Autonomic Society Virtual Meeting 2021   Benzinga
07:31AM EST  Alterity Therapeutics Announces Presentation of ATH434 at the American   PR Newswire
Nov 5, 2021
03:13AM EDT  Alterity Therapeutics : ATH434 Presents Novel Mechanism Of Action For Treatment Of Neurodegenerative Diseases   RTTNews
02:58AM EDT  Alterity Therapeutics Announces New Publications Providing Further Evidence of   PR Newswire
Nov 4, 2021
07:53AM EDT  Alterity Therapeutics Highlights New Publications On ATH434 To Treat Neurodegenerative Diseases   Benzinga
07:31AM EDT  Alterity Therapeutics Announces New Publications Providing Further Evidence of   PR Newswire
Oct 29, 2021
06:15AM EDT  Alerity Therapeutics 6-K Shows Cash Position Of $41.3M As Of Sept. 30, 2021, Operating Cash Outflows A$4.9M   Benzinga
02:51AM EDT  Appendix 4C - Q1 FY22 Quarterly Cash Flow Report   PR Newswire
Oct 26, 2021
05:39AM EDT  Alterity Therapeutics Granted U.S. Patent #11,155,547 'Compounds for and methods of treating diseases'   Benzinga
Oct 19, 2021
05:09PM EDT  Alterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development   PR Newswire
04:51AM EDT  Alterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development Program; Clinical Trial to Enroll Patients with Early-stage Multiple Systems Atrophy   Benzinga
Sep 20, 2021
10:52AM EDT  Alterity Highlights Presentation Of Biomarker Data At International Parkinson And Movement Disorder Society Congress 2021   Benzinga
10:52AM EDT  Alterity Announces Presentation of Biomarker Data at the International   PR Newswire
Aug 20, 2021
10:02AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For August 20, 2021   Benzinga
07:27AM EDT  Benchmark Initiates Coverage On Alterity Therapeutics with Speculative Buy Rating, Announces Price Target of $4   Benzinga
Aug 4, 2021
08:42AM EDT  Alterity:US Patent To Expand Portfolio Of Compounds For Neurodegenerative Diseases Including Alzheimer's And Parkinson's   RTTNews
08:40AM EDT  Compounds for Neurodegenerative Diseases including Alzheimer's and Parkinson's   PR Newswire
05:22AM EDT  Alterity Therapeutics Announced New US Patent to Expand its Portfolio of Compounds for Neurodegenerative Diseases including Alzheimer's and Parkinson's   Benzinga
Jul 30, 2021
09:06AM EDT  Appendix 4C - Q4 FY21 Quarterly Cash Flow Report   PR Newswire
Jul 15, 2021
10:08AM EDT  Alterity Therapeutics Says Treatment With ATH434   RTTNews
09:56AM EDT  Alterity : ATH434 Reduces -synuclein Related Neurodegeneration In Murine Model Of Multiple System Atrophy   RTTNews
09:54AM EDT  Alterity Therapeutics Highlights Publication Of Data; Says Data Demonstrates ATH434 Is Neuroprotective And Improves Motor Function   Benzinga
09:53AM EDT  Alterity Therapeutics Announces Publication of Data Demonstrating ATH434 is   PR Newswire
Jul 2, 2021
02:46PM EDT  Mid-Afternoon Market Update: Silver Rises 2%; Alector Shares Spike Higher   Benzinga
12:18PM EDT  Mid-Day Market Update: Dow Surges Over 100 Points; Arrowhead Pharmaceuticals Shares Plummet   Benzinga
10:28AM EDT  Mid-Morning Market Update: Markets Edge Higher; US Economy Adds 850,000 Jobs In June   Benzinga
05:32AM EDT  Alterity Therapeutics Australia Filing Shows Proposed Offering of 322,857,900 Shares   Benzinga
Jul 1, 2021
07:51AM EDT  Alterity Therapeutics Granted New US Patent Targeting Neurodegenerative Diseases Incl Alzheimer's And Parkinson's   RTTNews
07:50AM EDT  Alterity Therapeutics granted a new US patent targeting major neurodegenerative   PR Newswire
06:24AM EDT  Alterity Therapeutics Shares Trading +70% Premarket After Company Announced it was Granted a New Us Patent Targeting Major Neurodegenerative Diseases Including Alzheimer's and Parkinson's   Benzinga
Jun 23, 2021
09:26AM EDT  Alterity Therapeutics Receives European Union Regulatory Guidance For ATH434 Phase 2 Trial   RTTNews
09:22AM EDT  Alterity Therapeutics Says Received EU Regulatory Guidance For ATH434 Phase 2 Clinical Trial   Benzinga
09:22AM EDT  Alterity Therapeutics Limited Received European Union Regulatory Guidance for   PR Newswire
Apr 29, 2021
08:31AM EDT  Alterity Therapeutics Limited Appendix 4C - Q3 FY21 Quarterly Cash Flow Report   PR Newswire
Apr 21, 2021
09:25AM EDT  Alterity's Stock Is Trading Higher As ATH434 Preserves Neurons, Motor Performance In Animal Model With Neurodegenerative Disorder   Benzinga
08:37AM EDT  Alterity Therapeutics To Present Animal Data In Support Of ATH434 At American Academy of Neurology Meeting   Benzinga
08:37AM EDT  ATH434 protects brain cells and improves motor function in Parkinsonian disorder   PR Newswire
Feb 26, 2021
07:45AM EST  Alterity to present at the 7th International Congress of Multiple System Atrophy   PR Newswire
Feb 9, 2021
08:57AM EST  Alterity Announces Funding From Michael J. Fox Foundation For ATH434 Dose Optimization   RTTNews
08:56AM EST  Alterity Therapeutics Announces $495K In Funding From Michael J. Fox Foundation For ATH434 Dose Optimization For Parkinson's Disease Clinical Trials   Benzinga
08:54AM EST  Alterity Therapeutics announces funding from Michael J. Fox Foundation for   PR Newswire
01:47AM EST  ATHE Gets Funded For Parkinson's Research, No Safety   RTTNews
Jan 7, 2021
08:20AM EST  Alterity Therapeutics Appoints David Stamler As CEO   RTTNews
08:18AM EST  Alterity Therapeutics Appoints Dr. David Stamler CEO   Benzinga
08:02AM EST  Dr David Stamler Appointed CEO   PR Newswire
Dec 23, 2020
04:10PM EST  Alterity Therapeutics F-3 Shows Registration For ~882.5K ADS Offering Via Selling Shareholders   Benzinga
Dec 21, 2020
04:43PM EST  Alterity and UniQuest partner to reverse bacterial resistance to antibiotics   PR Newswire
Nov 23, 2020
12:19PM EST  The November Market Grinds Along   Benzinga
Nov 17, 2020
10:38AM EST  Mid-Morning Market Update: Markets Open Lower; Walmart Beats Q3 Views   Benzinga
Nov 16, 2020
02:36PM EST  Mid-Afternoon Market Update: Dow Rises 360 Points; Alterity Therapeutics Shares Spike Higher   Benzinga
01:11PM EST  Yahoo Finance Trending Stocks For Monday, Nov. 16, 2020: MRNA, WMT, SPCE, BA, PFE, JD, ATHE, TSM, BNTX, TGT, NVAX, HDS, INO, IBIO, XOM, MU, PANW, HPR, TSN, CCL, CAN, GP, BBVA, MMEDF, WWR, UBER, O, RCL, RAPT   Benzinga
12:37PM EST  Mid-Day Market Update: Crude Oil Surges 3.5%; Gulfport Energy Shares Plunge   Benzinga
10:06AM EST  Shares of Australia-based Alterity Therapeutics Ltd. (ATHE) are surging more than 152 percent or $1.75 in Monday's morning trade at $2.90.   RTTNews
08:42AM EST  Alterity announces approval of US patent for next generation compounds to treat   PR Newswire
06:25AM EST  Alterity Shares Rise 200% Premarket; Co Announced Approval Sunday of US Patent for Next Generation Compounds to Treat Neurodegenerative Diseases   Benzinga
Oct 26, 2020
10:04PM EDT  Alterity commences enrolling Multiple System Atrophy patients in bioMUSE Study   PR Newswire
Oct 16, 2020
06:47AM EDT  Alerity Shares To Resume Trade At 7 a.m. EDT   Benzinga
06:47AM EDT  Alterity Therapeutics Raises $35M In Placement With Institutional Investors   Benzinga
Oct 5, 2020
04:11PM EDT  Alterity Therapeutics F-3 Shows Registration For $50M Mixed Securities Offering   Benzinga
Aug 11, 2020
10:43AM EDT  Alterity Shares Spike Higher; Co. Granted U.S. Patent No. 10,738,050 Titled '4H-pyrido[1,2-A]pyrimidin-4-one compounds for their use as pharmaceutical agents or compositions in the treatment of neurological disorders'   Benzinga
Aug 5, 2020
03:10PM EDT  Why Alterity's Stock Is Trading Lower Today   Benzinga
Aug 4, 2020
04:45PM EDT  04:45 Tuesday, August 04, 2020   RTTNews
02:30PM EDT  Mid-Afternoon Market Update: Crude Oil Rises 2.5%; Harmonic Shares Climb On Upbeat Results   Benzinga
12:00PM EDT  Mid-Day Market Update: Dow Surges Over 100 Points; DBV Technologies Shares Plummet   Benzinga
11:34AM EDT  Why Alterity's Stock Is Trading Higher Today   Benzinga
09:59AM EDT  Shares of Alterity Therapeutics Limited (ATHE) are gaining almost 144 percent or $1.94 in Tuesday's morning trade at $3.29, after earlier touching a new 52-week high of $3.84.   RTTNews
06:26AM EDT  Alterity Therapeutics Shares Rise 168% Premarket; Co to Present at Two Upcoming Conferences and Report Positive Data for its Treatment for Parkinson's Disorder MSA   Benzinga
06:22AM EDT  Alterity Therapeutics Shares Rise 168% Premarket; Co to Present at Two Upcoming Conferences and Report and Report Positive Data for its Treatment for Parkinson's Disorder MSA   Benzinga
02:59AM EDT  Alterity Therapeutics Shares Surge As Company Says Animal Testing Data Positive For MSA Drug   Benzinga
Aug 3, 2020
10:07PM EDT  Alterity : New Data Independently Confirms And Extends Laboratory Findings And Expands Safety Profile Of ATH434   RTTNews
09:34PM EDT  New data independently confirms and extends laboratory findings and expands   PR Newswire
Jul 30, 2020
06:50PM EDT  Alterity Releases Appendix 4C - Q4 FY20 Quarterly Cash Flow Report   PR Newswire


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC